[go: up one dir, main page]

WO1998025643A3 - Neuropeptide als modulatoren zur zelldifferenzierung und proliferation - Google Patents

Neuropeptide als modulatoren zur zelldifferenzierung und proliferation Download PDF

Info

Publication number
WO1998025643A3
WO1998025643A3 PCT/EP1997/006901 EP9706901W WO9825643A3 WO 1998025643 A3 WO1998025643 A3 WO 1998025643A3 EP 9706901 W EP9706901 W EP 9706901W WO 9825643 A3 WO9825643 A3 WO 9825643A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
npy
cgrp
granulation
substance
Prior art date
Application number
PCT/EP1997/006901
Other languages
English (en)
French (fr)
Other versions
WO1998025643A2 (de
Inventor
Konrad Wolf
Irmgard Guertner
Original Assignee
Konrad Wolf
Irmgard Guertner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konrad Wolf, Irmgard Guertner filed Critical Konrad Wolf
Priority to DE19781388T priority Critical patent/DE19781388D2/de
Priority to AU58555/98A priority patent/AU5855598A/en
Publication of WO1998025643A2 publication Critical patent/WO1998025643A2/de
Publication of WO1998025643A3 publication Critical patent/WO1998025643A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/34—Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/83—Tachykinins, e.g. substance P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/835—Neuropeptide Y [NPY]; Peptide YY [PYY]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ein Arzneimittel zur Behandlung von Gewebeläsionen, Differenzierungs- oder Granulationsdefiziten sowie Stoffwechselstörungen enthält als Wirkstoff Calcitonin-gene related peptide (CGRP) oder/und Substanz P oder/und Neuropeptid Y (NPY) gegebenenfalls mit üblichen pharmazeutischen Hilfs- oder/und Trägerstoffen. Zur Herstellung von autologen Gewebeäquivalenten werden einem Patienten entnommene Vorläuferzellen in vitro unter Zugabe von CGRP oder/und Substanz P oder/und NPY kultiviert. Derartige Gewebeäquivalente dienen erfindungsgemäß als Implantate im Bereich der Therapie von Gewebedefekten, Gewebeläsionen oder Granulationsstörungen.
PCT/EP1997/006901 1996-12-13 1997-12-10 Neuropeptide als modulatoren zur zelldifferenzierung und proliferation WO1998025643A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19781388T DE19781388D2 (de) 1996-12-13 1997-12-10 Neuropeptide als Modulatoren zur Zelldifferenzierung und Proliferation
AU58555/98A AU5855598A (en) 1996-12-13 1997-12-10 Neuropeptides as modulators for cell differentiation and proliferation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19652033.9 1996-12-13
DE19652033A DE19652033A1 (de) 1996-12-13 1996-12-13 Neuropeptid (CGRP) als Modulator zur Zelldifferenzierung und Proliferation

Publications (2)

Publication Number Publication Date
WO1998025643A2 WO1998025643A2 (de) 1998-06-18
WO1998025643A3 true WO1998025643A3 (de) 1998-10-29

Family

ID=7814701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006901 WO1998025643A2 (de) 1996-12-13 1997-12-10 Neuropeptide als modulatoren zur zelldifferenzierung und proliferation

Country Status (3)

Country Link
AU (1) AU5855598A (de)
DE (2) DE19652033A1 (de)
WO (1) WO1998025643A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569654B2 (en) * 1998-09-18 2003-05-27 Massachusetts Institute Of Technology Electroactive materials for stimulation of biological activity of stem cells
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US20090028834A1 (en) * 2007-07-27 2009-01-29 Hal Siegel Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance P or an analog thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156772A2 (de) * 1984-03-27 1985-10-02 Sandoz Ag Pharmazeutische Verwendung für CGRPs
EP0188400A2 (de) * 1985-01-16 1986-07-23 Ciba-Geigy Ag Oligopeptide sowie Zwischenprodukte und Verfahren zu ihrer Herstellung
DE3810803A1 (de) * 1988-03-30 1989-10-12 Battelle Institut E V Verfahren zur herstellung eines synthetischen knochenmaterials mit koerpereigenen eigenschaften
EP0355793A2 (de) * 1988-08-26 1990-02-28 Merrell Pharmaceuticals Inc. Neuropeptid Y-Agonisten und partielle Agonisten
EP0672420A1 (de) * 1992-08-26 1995-09-20 Asahi Kasei Kogyo Kabushiki Kaisha Wundheilmittel
US5616562A (en) * 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156772A2 (de) * 1984-03-27 1985-10-02 Sandoz Ag Pharmazeutische Verwendung für CGRPs
EP0188400A2 (de) * 1985-01-16 1986-07-23 Ciba-Geigy Ag Oligopeptide sowie Zwischenprodukte und Verfahren zu ihrer Herstellung
DE3810803A1 (de) * 1988-03-30 1989-10-12 Battelle Institut E V Verfahren zur herstellung eines synthetischen knochenmaterials mit koerpereigenen eigenschaften
EP0355793A2 (de) * 1988-08-26 1990-02-28 Merrell Pharmaceuticals Inc. Neuropeptid Y-Agonisten und partielle Agonisten
US5616562A (en) * 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
EP0672420A1 (de) * 1992-08-26 1995-09-20 Asahi Kasei Kogyo Kabushiki Kaisha Wundheilmittel

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERNARD, G.W. ET AL: "The osteogenic stimulating effect of neuroactive calcitonin gene-related peptide", PEPTIDES, vol. 11, no. 4, 1990, pages 625 - 632, XP002065012 *
BJURHOLM A. ET AL: "Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1 and Saos-2) and primary bone cells", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 7, no. 9, 1992, pages 1011 - 1019, XP002065013 *
BJURHOLM A. ET AL: "The ocuurence of neuropeptides at different stages of DBM-induced heterotopic bone formation", BONE AND MINERAL, vol. 10, 1990, pages 95 - 107, XP002074555 *
DUNNICK C.A. ET AL: "Substance P has a role in neurogenic mediation of human burn wound healing", JOURNAL OF BURN CARE & REHABILITATION, vol. 17, no. 5, October 1996 (1996-10-01), pages 390 - 396, XP002074553 *
KHALIL Z. ET AL: "Sensory peptides as Neuromodulators of wound healing in aged rats", THE JOURNALS OF GERONTOLOGY, vol. 51A, no. 5, September 1996 (1996-09-01), pages B354 - B361, XP002074552 *
RAMESHWAR P. ET AL: "In vitro stimulatory effect of substance P on hematopoiesis", BLOOD, vol. 81, no. 2, 1993, pages 391 - 397, XP002074551 *
TRANTOR I.R. ET AL: "The effects of neuropeptides (Calcitonin gene-related peptide and Substance P) on cultured human pulp cells", JOURNAL OF DENTAL RESEARCH, vol. 74, no. 4, 1995, pages 1066 - 1071, XP002074554 *
VIGNERY A. ET AL: "The neuropeptide calcitonin gene related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts", BONE, vol. 18, no. 4, April 1996 (1996-04-01), pages 331 - 335, XP002065011 *

Also Published As

Publication number Publication date
DE19652033A1 (de) 1998-06-18
AU5855598A (en) 1998-07-03
DE19781388D2 (de) 2001-05-10
WO1998025643A2 (de) 1998-06-18

Similar Documents

Publication Publication Date Title
Bai et al. Regulation of inflammatory microenvironment using a self-healing hydrogel loaded with BM-MSCs for advanced wound healing in rat diabetic foot ulcers
RU2705211C2 (ru) Композиция и способ лечения кожных рубцов
Diegelmann et al. The role of macrophages in wound repair: a review
Adeghate et al. Novel biological therapies for the treatment of diabetic foot ulcers
CA2171266C (en) Stable transglutaminase preparations and processes for producing them
Chehelcheraghi et al. Effects of acellular amniotic membrane matrix and bone marrow-derived mesenchymal stem cells in improving random skin flap survival in rats
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
IL77096A (en) Pharmaceutical compositions for enhancing wound healing comprising angiogene and growth factors
DE59908745D1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
CN101370821A (zh) 新型肽及其用途
WO2000030622A3 (de) Verwendung von dialkylfumaraten zur behandlung von host-versus-graft reaktionen und von autoimmunerkrankungen
WO2001076615A3 (en) Cxcr4 agonist treatment of hematopoietic cells
Lee et al. Effects of hepatocyte growth factor on collagen synthesis and matrix metalloproteinase production in keloids
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
AT500670A1 (de) Arzneimittel zur lokalen anwendung
Huang et al. Combination therapy of hydrogel and stem cells for diabetic wound healing
Xing et al. Preparation of an acellular spinal cord scaffold to improve its biological properties
AU5283890A (en) Fibroblast growth factor (fgf)-based stabilized compositions
Losi et al. Healing effect of a fibrin-based scaffold loaded with platelet lysate in full-thickness skin wounds
Lau et al. Pharmaceutical perspectives of impaired wound healing in diabetic foot ulcer
Zhang et al. Matrix Metalloproteinase‐Responsive Hydrogel with On‐Demand Release of Phosphatidylserine Promotes Bone Regeneration Through Immunomodulation
Wang et al. Adipose‐derived stem cells enriched with therapeutic mRNA TGF‐β3 and IL‐10 synergistically promote scar‐less wound healing in preclinical models
Hu et al. Co-transfection with BMP2 and FGF2 via chitosan nanoparticles potentiates osteogenesis in human adipose-derived stromal cells in vitro
WO1998025643A3 (de) Neuropeptide als modulatoren zur zelldifferenzierung und proliferation
ATE517121T1 (de) Integrin-heterodimer und eine alpha-untereinheit davon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REF Corresponds to

Ref document number: 19781388

Country of ref document: DE

Date of ref document: 20010510

WWE Wipo information: entry into national phase

Ref document number: 19781388

Country of ref document: DE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642